Lucia Moiola1, Paulus S Rommer2, Uwe K Zettl3. 1. Department of Neurology, Multiple Sclerosis Center, IRCCS Ospedale San Raffaele, Milan, Italy. 2. Department of Neurology, Medical University of Vienna, Vienna, Austria. 3. Neuroimmunology Section, Department of Neurology, University of Rostock, Rostock, Germany.
Abstract
PURPOSE OF REVIEW: To summarize the currently known side effects of the approved therapies of multiple sclerosis and to suggest monitoring procedures. RECENT FINDINGS: The progress in the treatment of multiple sclerosis with new very effective therapies is accompanied by a number of side effects. Some of these have already been described in the approval studies, but some only after approval in a real world situation. The reason for this is the short duration of the clinical studies, the very heterogeneous patient profile in the real world setting with a number of comorbidities, pretherapies, and wider age range. The side effects may occur during application of therapies or afterwards during the course of the treatment. The side effects may range from mild infections, mild laboratory abnormalities, secondary autoimmune diseases to life-threatening side effects such as progressive multifocal leukoencephalopathy. SUMMARY: It has to be pointed out that these side effects are not to be considered as final and neurologists should be vigilant against new unknown side effects. The doctor should be aware of these undesirable effects, should weigh the benefits of the therapies against the risks, but at the same time she/he should keep in mind that multiple sclerosis can be a very disabling disease if not treated properly.
PURPOSE OF REVIEW: To summarize the currently known side effects of the approved therapies of multiple sclerosis and to suggest monitoring procedures. RECENT FINDINGS: The progress in the treatment of multiple sclerosis with new very effective therapies is accompanied by a number of side effects. Some of these have already been described in the approval studies, but some only after approval in a real world situation. The reason for this is the short duration of the clinical studies, the very heterogeneous patient profile in the real world setting with a number of comorbidities, pretherapies, and wider age range. The side effects may occur during application of therapies or afterwards during the course of the treatment. The side effects may range from mild infections, mild laboratory abnormalities, secondary autoimmune diseases to life-threatening side effects such as progressive multifocal leukoencephalopathy. SUMMARY: It has to be pointed out that these side effects are not to be considered as final and neurologists should be vigilant against new unknown side effects. The doctor should be aware of these undesirable effects, should weigh the benefits of the therapies against the risks, but at the same time she/he should keep in mind that multiple sclerosis can be a very disabling disease if not treated properly.
Authors: Silvan Elias Langhorst; Niklas Frahm; Michael Hecker; Pegah Mashhadiakbar; Barbara Streckenbach; Julia Baldt; Felicita Heidler; Uwe Klaus Zettl Journal: J Pers Med Date: 2022-04-23
Authors: Oliver Neuhaus; Wolfgang Köhler; Florian Then Bergh; Wolfgang Kristoferitsch; Jürgen Faiss; Thorsten Rosenkranz; Dirk Reske; Robert Patejdl; Hans-Peter Hartung; Uwe K Zettl Journal: Biomolecules Date: 2021-03-07
Authors: Paula Bachmann; Niklas Frahm; Jane Louisa Debus; Pegah Mashhadiakbar; Silvan Elias Langhorst; Barbara Streckenbach; Julia Baldt; Felicita Heidler; Michael Hecker; Uwe Klaus Zettl Journal: Pharmaceutics Date: 2022-03-08 Impact factor: 6.321